141 related articles for article (PubMed ID: 9262356)
1. Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin.
Witte DG; Brune ME; Katwala SP; Milicic I; Kerwin JF; Hancock AA
J Pharmacol Exp Ther; 1997 Aug; 282(2):891-8. PubMed ID: 9262356
[TBL] [Abstract][Full Text] [Related]
2. Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
Witte DG; Brune ME; Katwala SP; Milicic I; Stolarik D; Hui YH; Marsh KC; Kerwin JF; Meyer MD; Hancock AA
J Pharmacol Exp Ther; 2002 Feb; 300(2):495-504. PubMed ID: 11805209
[TBL] [Abstract][Full Text] [Related]
3. Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity.
Hancock AA; Brune ME; Witte DG; Marsh KC; Katwala S; Milicic I; Ireland LM; Crowell D; Meyer MD; Kerwin JF
J Pharmacol Exp Ther; 1998 May; 285(2):628-42. PubMed ID: 9580607
[TBL] [Abstract][Full Text] [Related]
4. Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Brune ME; Katwala SP; Milicic I; Buckner SA; Ireland LM; Kerwin JF; Hancock AA
Pharmacology; 1996 Dec; 53(6):356-68. PubMed ID: 9032800
[TBL] [Abstract][Full Text] [Related]
5. Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.
Brune ME; Katwala SP; Milicic I; Witte DG; Kerwin JF; Meyer MD; Hancock AA; Williams M
J Pharmacol Exp Ther; 2002 Feb; 300(2):487-94. PubMed ID: 11805208
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin.
Sato S; Ohtake A; Matsushima H; Saitoh C; Usuda S; Miyata K
J Pharmacol Exp Ther; 2001 Mar; 296(3):697-703. PubMed ID: 11181895
[TBL] [Abstract][Full Text] [Related]
7. Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs.
Sharma R; Ahuja VM; Fahim M
Indian J Exp Biol; 2004 Dec; 42(12):1195-9. PubMed ID: 15623230
[TBL] [Abstract][Full Text] [Related]
8. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
9. [Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats--study of the selectivity for lower urinary tract].
Tatemichi S; Kobayashi K; Maruyama I; Kobayashi M; Yamazaki Y; Shibata N
Yakugaku Zasshi; 2006 Mar; 126 Spec no.():217-23. PubMed ID: 16518086
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.
Nagarathnam D; Wetzel JM; Miao SW; Marzabadi MR; Chiu G; Wong WC; Hong X; Fang J; Forray C; Branchek TA; Heydorn WE; Chang RS; Broten T; Schorn TW; Gluchowski C
J Med Chem; 1998 Dec; 41(26):5320-33. PubMed ID: 9857099
[TBL] [Abstract][Full Text] [Related]
11. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.
Pulito VL; Li X; Varga SS; Mulcahy LS; Clark KS; Halbert SA; Reitz AB; Murray WV; Jolliffe LK
J Pharmacol Exp Ther; 2000 Jul; 294(1):224-9. PubMed ID: 10871316
[TBL] [Abstract][Full Text] [Related]
12. Effects of tamsulosin on hypogastric nerve stimulation-induced intraurethral pressure elevation in male and female dogs under anesthesia.
Ohtake A; Sato S; Saitoh C; Yuyama H; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 497(3):327-34. PubMed ID: 15336951
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
Beretta-Piccoli C; Ferrier C; Weidmann P
J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
[TBL] [Abstract][Full Text] [Related]
14. RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.
Nanda K; Naruganahalli KS; Gupta S; Malhotra S; Tiwari A; Hegde LG; Jain S; Sinha N; Gupta JB; Chugh A; Anand N; Ray A
Eur J Pharmacol; 2009 Apr; 607(1-3):213-9. PubMed ID: 19239913
[TBL] [Abstract][Full Text] [Related]
15. In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs.
Noguchi Y; Ohtake A; Suzuki M; Sasamata M
Eur J Pharmacol; 2008 Feb; 580(1-2):256-61. PubMed ID: 18078926
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers.
Campanero MA; Sádaba B; Muñoz-Juarez MJ; Quetglas EG; Azanza JR
Clin Drug Investig; 2008; 28(3):139-47. PubMed ID: 18266399
[TBL] [Abstract][Full Text] [Related]
17. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Lepor H; Gup DI; Baumann M; Shapiro E
Urology; 1988 Dec; 32(6 Suppl):21-6. PubMed ID: 2462301
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
[TBL] [Abstract][Full Text] [Related]
19. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin.
Sennello LT; Sonders RC; Glassman HN; Jordan DC; Luther RR; Tolman KG
Clin Ther; 1988; 10(5):600-7. PubMed ID: 2908805
[TBL] [Abstract][Full Text] [Related]
20. Baroreceptor mediated blood pressure regulation is not affected during dose dependent inhibition of prostatic contractions by terazosin.
Pawar A; Fahim M
Indian J Physiol Pharmacol; 2004 Oct; 48(4):419-27. PubMed ID: 15907050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
